Assembly Research And Ddevelopement To Revenue from 2010 to 2026
| ASMB Stock | USD 28.30 -0.91 -3.12% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 1.77 | Current Value 1.68 | Quarterly Volatility 2.31019949 |
Macro event markers
Use the financial statements timeline for Assembly Biosciences to frame performance drivers and balance sheet structure. This context pairs drivers like Depreciation And Amortization of 245 K, Interest Expense of 544.1 K or Selling General Administrative of 17.8 M and ratios such as Price To Sales Ratio of 3.63, Dividend Yield of 0.0 or PTB Ratio of 1.56 with Assembly Biosciences Valuation and Volatility views.
Assembly | Research And Ddevelopement To Revenue | Build AI portfolio with Assembly Stock |
Analyzing Assembly Biosciences's Research And Ddevelopement To Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research And Ddevelopement To Revenue has evolved provides context for assessing Assembly Biosciences's current valuation and future prospects.
Latest Assembly Biosciences' Research And Ddevelopement To Revenue Growth Pattern
Below is the plot of the Research And Ddevelopement To Revenue of Assembly Biosciences over the last few years. It is Assembly Biosciences' Research And Ddevelopement To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assembly Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Research And Ddevelopement To Revenue | 10 Years Trend |
|
Research And Ddevelopement To Revenue |
| Timeline |
Assembly Research And Ddevelopement To Revenue Regression Statistics
| Arithmetic Mean | 4.76 | |
| Geometric Mean | 4.17 | |
| Coefficient Of Variation | 48.55 | |
| Mean Deviation | 1.44 | |
| Median | 4.90 | |
| Standard Deviation | 2.31 | |
| Sample Variance | 5.34 | |
| Range | 9.6064 | |
| R-Value | -0.20 | |
| Mean Square Error | 5.47 | |
| R-Squared | 0.04 | |
| Significance | 0.45 | |
| Slope | -0.09 | |
| Total Sum of Squares | 85.39 |
Assembly Research And Ddevelopement To Revenue History
Stock Overview, Methodology & Data Sources
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people. Market structure and macro sensitivity help explain how Assembly Biosciences behaves across regimes. Market sensitivity remains generally comparable to wider market conditions. Assembly Biosciences has a market cap of 462.02 M, ROE of -36.94%.
Methodology
Unless otherwise specified, financial data for Assembly Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Assembly (USA Stocks:ASMB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Assembly Biosciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Assembly Stock Analysis
A comprehensive view of Assembly Biosciences starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Assembly Biosciences Stock. Selected reports below provide context for Assembly Stock:Use Assembly Biosciences Correlation to compare Assembly Biosciences against competitors. The view supports competitor context. Before investing in Assembly Stock, review our How to Buy Assembly Biosciences guide for key considerations.Analysis related to Assembly Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Earnings Share -4.60 | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Understanding Assembly Biosciences includes distinguishing between market value and book value, where book value reflects Assembly's accounting equity. Assembly Biosciences' market capitalization is 462.02 M. A P/B ratio of 2.53 indicates the market values Assembly Biosciences above its accounting book value. Enterprise value stands at 232.22 M. Intrinsic value reflects what Assembly Biosciences' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Assembly Biosciences' value from its trading price, which are computed with different methods. For Assembly Biosciences, key inputs include a P/B ratio of 2.53, a profit margin of -103.65%, ROE of -36.94%, and revenue of 28.52 M. The quoted price is simply the exchange level where supply meets demand.